XNAS · Healthcare · Biotechnology
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-19 | Q1 2026 | -0.71 | -0.69 | +2.82% | $0 | ✅ Beat | +1.60% | +7.01% | — |
| 2026-02-26 | Q4 2025 | -0.75 | -0.73 | +2.67% | $0 | mixed | -0.47% | -8.03% | -15.22% |
| 2025-11-06 |
| Q3 2025 |
| -0.76 |
| -0.74 |
| +2.63% |
| $0 |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-11 | Q2 2025 | -0.74 | -0.72 | +2.70% | $0 | ✅ Beat | +1.00% | +6.47% | +5.17% |
| 2025-02-27 | Q4 2024 | -0.91 | -0.67 | +26.37% | $0 | ✅ Beat | -10.97% | -12.53% | -26.91% |
| 2024-08-01 | Q2 2024 | -0.68 | -0.59 | +13.24% | $0 | ✅ Beat | -6.26% | -4.50% | +7.67% |
| 2024-05-07 | Q1 2024 | -0.70 | -0.68 | +2.86% | $0 | ✅ Beat | +12.17% | +17.21% | +26.47% |
| 2024-02-27 | Q4 2023 | -0.80 | -0.86 | -7.50% | $0 | ❌ Miss | — | — | — |
Showing last 8 quarters.